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The discovery of the new antibiotic teixobactin has been timely in
the race for unearthing novel antibiotics wherein the emergence of
drug resistant bacteria poses a serious threat worldwide. Herein, we
present the total syntheses and biological activities of two teixobactin
analogues. This approach is simple, eﬃcient and has several
advantages: it uses commercially available building blocks (except
AllocHN-D-Thr-OH), has a single purification step and a good
recovery (22%). By using this approach we have synthesised two
teixobactin analogues and established that the D-amino acids are critical
for the antimicrobial activity of these analogues. With continuing
high expectations from teixobactin, this work can be regarded as
a stepping stone towards an in depth study of teixobactin, its
analogues and the quest for synthesising similar molecules.
The decreased potency of drugs such as penicillin,1 vancomycin2
and oxacillin3 due to their excessive use is a consequence of
the emergence of drug resistant bacteria. It has been predicted
that antimicrobial resistance (AMR) will have disastrous conse-
quences and it is estimated that by 2050 an additional 10 million
people yearly could succumb to drug resistant infections.4 The
recently published article in Nature5 describing the discovery
of teixobactin has provided a much needed breakthrough in the
challenging field of antibiotic peptides. The bacteria against
which it is eﬀective have, thus far, not shown any detectable
resistance to teixobactin. Moreover, given themultiplemechanisms
of attack by teixobactin described by Su¨ssmuth6 resistance is
unlikely in the near future. Unfortunately, although teixobactin
provides somemuch needed answers, the problem is far from over.
Organic chemists have worked round the clock to synthesise
novel antibiotics and although progress has been steady,
bacteria have time and again confounded even the best in this
field.7 This is where the multichannel device, iChip,8 has made
a considerable contribution enabling the identification of
molecules like teixobactin, some of which could be active
against drug resistant bacteria. However, the iChip device has
its limitations. The probability of finding an antibiotic is
extremely low (107 percent) and even with high-throughput
screening, which takes considerable time and resources, there
is no guarantee when will be the discovery of the next drug like
teixobactin. Undeniably, breakthroughs via organic synthesis
have to be made to keep the drug resistance problem under
check. The time for this is indeed now and teixobactin is a good
starting point. This study is aimed at doing so and provides a
general approach through which, not only teixobactin, but also
other analogues can be synthesised. The total synthesis of
teixobactin will give access to analogues which nature cannot
provide us with and therefore an organic synthesis approach
to the bigger problem at hand should not be prematurely
discarded. It is to be noted that during the preparation of
this manuscript a report from the Albericio group appeared
describing the synthesis of teixobactin analogue 1 obtained in a
6% yield. Moreover, the role of the D-amino acids have not been
proven.9 Our work presents an eﬃcient syntheses of both the D
and L versions of the analogues of teixobactin (22% yield for 1)
and their role in antimicrobial activity.
Since teixobactin has been fully characterised by NMR and
LC-MS, the structural complexity of teixobactin can be described
as moderate to diﬃcult. It has also been described as an unusual
depsipeptide due to the presence of the non-natural amino acids
L-allo-enduracididine and N-methylphenylalanine along with
four D-amino acids (Fig. 1). Despite not possessing a lipid tail,
the commercial unavailability of the enduracididine amino acid
makes the total synthesis of the molecule more time consuming
than expected.10 The commercially available natural amino acid
arginine (a linear guanidine) is the closest structural match suitable
for the replacement of the L-allo-enduracididine (a cyclic guanidine)
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as can be seen in Fig. 1 (green). In this work, arginine was
selected as a replacement of enduracididine for synthesis of
teixobactin analogue 1. A first approach towards tackling this
molecule was to synthesise the complete peptide on solid phase
and cyclise post-cleavage from the resin via an ester bond (ESI,†
Fig. S1). This route has been used with success for the synthesis
of the analogues of callipeltin B.11
Following this strategy, a fully protected linear peptide was
synthesised and cleaved from the resin without cleaving
the protecting groups. However, the synthesis failed at the
esterification step. Several conditions have been tested for the
esterification as described in Table S1 (ESI†). Unfortunately,
none of them yielded the esterified product. This could be due
to the steric bulk of protecting groups on the amino acids. This
led to the conclusion that a direct and linear route is not
the way to cyclisation. Therefore a new second synthetic route
had been devised which involves cyclisation via amide bond
formation (Fig. 1b). For the total synthesis of analogue 1, an
optimised pathway for the synthesis of the core ring structure
(2) of teixobactin was required. Therefore, the initial eﬀorts
were focussed on obtaining this key fragment (Fig. 2).
For optimisation of the synthesis, we chose Wang resin. Fmoc-
Ala-OH was loaded onto this resin via ester bond formation.
The unreacted resin was capped using 10% acetic anhydride/
diisopropylethylamine (Ac2O/DIPEA) followed by (a) the attach-
ment of Fmoc-D-Thr(Trt)-OH via amide bond formation and
subsequent (b) Fmoc removal. The orthogonal Alloc protecting
group was installed on the amine (c) followed by (d) trityl group
removal by 1 : 5 : 96 TFA : TIS : DCM and proceeded with (e) the
challenging esterification reaction between Ile and Thr. It is to
be noted that excess Ile and base were required to drive the
reaction to completion.12 This was succeeded by (f) amide bond
formation using Arg and subsequent (g) cleavage from the resin
using 95 : 2.5 : 2.5 TFA : TIS :H2O. The final step was (h) the
amide bond formation between Arg and Ala which proceeds
smoothly yielding the desired cyclised fragment. This approach
was then slightly modified and used for the total synthesis of
the teixobactin analogue 1 as described in Fig. 3.
The approach used in this work involves synthesising the
peptide completely on solid phase and only a single purification
was required after the final cleavage. The synthesis of building
block AllocHN-D-Thr-OH (modified from ref. 13) was also reported
for first time and which can be directly coupled to the resin without
protecting the amino acid side chain. 2-Chlorotritylchloride resin
was chosen instead of Wang resin as the peptide could be cleaved
oﬀ from the resin without removing the side chain protecting
groups of the attached amino acids.14
(a) The first amino acid loaded on the resin in this case is
Fmoc-Ala-OH followed by (b) an amide bond coupling with
Alloc-D-Thr-OH. (c) Fmoc-Ile-OH is then coupled at this stage via an
ester bond to the free –OH side chain of threonine. Next, (d)
arginine was coupled via an amide bond, the Fmoc protecting
group is removed and (e) the N-terminus is protected via a trityl
protecting group15 (combining cleavage and deprotection in a
single step) to facilitate the cleavage and cyclisation as described
in reactions (h and i). (f) The Alloc group protecting the N-terminus
of the threonine is then removed16 and (g) the peptide chain is built
via standard solid phase peptide synthesis (SPPS). Partial cleavage
was performed using 2 :5 :93 TFA :TIS :DCM followed by cyclisation
using 1-[bis(dimethylamino) methylene]-1H-1,2,3-triazolo[4,5-b]-
pyridinium 3-oxid hexafluorophosphate (HATU) as a coupling
reagent and DIPEA as a base in DMF for 1 h. The protecting
groups are then cleaved off using 95 : 2.5 : 2.5 TFA : TIS :H2O
yielding the desired peptide (22% recovery, refer ESI,† S10). After
successful synthesis of analogue 1, the general applicability of
Fig. 1 (a) (left) Structure of teixobactin. (b) (right) Structure of the teixobactin analogue 1 showing the bonds to be cleaved for the synthesis routes A (in
blue) and B (in red) and the structural diﬀerences (in green).
Fig. 2 Synthesis scheme for the core teixobactin fragment 2 starting from
Wang resin: (a) 10 eq. Fmoc-Ala-OH, 10 eq. DIC, 1 eq. DMAP, 10% Ac2O/
DIPEA in DMF followed by 20% piperidine in DMF. (b) 2.5 eq. Fmoc-D-Thr(Trt)-
OH, 2.5 HATU/5 eq. DIPEA, 3 h DMF followed by 20% piperidine in DMF.
(c) 4 eq. allyl chloroformate/8 eq. DIPEA in DCM, 1 h. (d) 1 : 5 :96 TFA :TIS :
DCM. 3 15min. (e) 10 eq. Fmoc-Ile-OH, 10 eq. DIC, 10mol% DMAP in DCM,
2 h followed by 10% Ac2O/DIPEA in DMF, followed by 20% piperidine in DMF.
(f) 4 eq. Fmoc-Arg(Pbf)-OH, 4 eq. HATU/8 eq. DIPEA in DMF, 1 h followed by
20% piperidine in DMF. (g) TFA :TIS :H2O = 95 :2.5 : 2.5, 1 h. (h) 1 eq. HATU/
10 eq. DIPEA in DMF, 1 h, monitored on HPLC.
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this approach was tested for the synthesis of analogue 3 (Fig. 4). In
analogue 3, the three D-amino acids residues (Phe, Gln and Ile)
were replaced by L-amino acid residues. The synthesis of analogue
3 also worked efficiently (17% recovery, refer ESI,† S10).
The detailed characterisation of 1 and 3 were performed using
LC-MS and NMR. The NMR spectra of product 1 (refer ESI,† page
S15) was shown to be identical as reported previously.5,9 The NOEs
of 1 were characteristic of a random coil, however, the NOEs of 3
suggested a considerable degree of structure.
The analogues 1 and 3 were evaluated for their antibacterial
activity. MIC results showed a trend similar to teixobactin
for analogue 1 against both Gram-positive and Gram-negative
bacteria. Analogue 3 was not active against Gram-negative
bacteria. Moreover, analogue 1 was 64 times more eﬀective
than analogue 3 (Table 1) against Gram-positive bacteria.
This diﬀerence in antibacterial activity has established that
the three D-amino acids residues of 1 are critical for the
antibacterial activity.
Fig. 3 Total synthesis of analogue 1 starting from 2-chlorotritylchloride resin: (a) 4 eq. Fmoc-Ala-OH/8 eq. DIPEA in DCM, 3 h. (b) 20% piperidine in DMF
followed by 3 eq. AllocHN-D-Thr-OH, 3 eq. HATU/6 eq. DIPEA. (c) 10 eq. Fmoc-Ile-OH, 10 eq. DIC, 5 mol% DMAP in DCM, 2 h followed by capping with
Ac2O/DIPEA 10% in DMF, 20% piperidine in DMF (d) 4 eq. Fmoc-Arg(Pbf)-OH, 4 eq. HATU/8 eq. DIPEA in DMF, 1 h followed by 20% piperidine in DMF
(e) 10 eq. Trt-Cl, 15% Et3N in DCM, 1 h. (f) 0.2 eq. Pd(PPh3)4/24 eq. PhSiH3 in DCM, 2  1 h. (g) Fmoc/Boc-AA(PG)-OH (AA = amino acid, PG = protecting
group), HATU/DIPEA followed by 20% piperidine in DMF. (h) TFA : TIS : DCM = 2 : 5 : 93, 2 h. (i) 1 eq. HATU/10 eq. DIPEA in DMF, 1 h, monitored on HPLC.
(j) TFA : TIS : H2O = 95 : 2.5 : 2.5, 1 h.
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In conclusion, this work reports eﬃcient total syntheses of two
teixobactin analogues (22% yield of teixobactin analogue 1). Analo-
gue 1 is identical to teixobactin in all aspects with the exception of
the L-allo-enduracididine amino acid. The methodology described
here is not specific to only one molecule, but it can also be used as
a general strategy for synthesis of other analogues of teixobactin.
The role of three D-amino acids has also been established. The
three D-amino acids present in the teixobactin analogue 1 but
absent in analogue 3 are critical for antibacterial activity. This work
also reports the synthesis of new AllocHN-D-Thr-OH building block
and has incorporated it as such in the syntheses of teixobactin
analogues. We believe that this work to be pivotal for the synthesis
of teixobactin and its analogues and therefore will be helpful to
address the current challenges of antimicrobial resistance.
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Fig. 4 Structure of analogue 3.
Table 1 MIC (mg ml1) for 1 and 3 and Teixobactin
Entry Organism 1 3 Teixobactin
1 S. aureus ATCC 25 923 2 128 0.25a
2 E. coli ATCC 25 922 64 GAWb 25
a MIC from ref. 5 was from a diﬀerent strain of S. aureus. b Growth in
all wells.
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